Literature DB >> 20455786

Development and evaluation of a complementary and alternative medicine use survey in African-Americans with acquired immune deficiency syndrome.

Ashli Owen-Smith1, Claire Sterk, Frances McCarty, Dana Hankerson-Dyson, Ralph Diclemente.   

Abstract

OBJECTIVES: The purpose of the current study was to develop and evaluate the psychometric properties of a culturally- and stage-of-disease-appropriate measure of complementary and alternative medicine (CAM) use among a population of African-American individuals with acquired immune deficiency syndrome (AIDS) using a mixed-method design.
DESIGN: Data were collected in two phases. In phase 1, qualitative data were used to refine an existing CAM measure for the specific study population in the present study. In phase 2, this refined instrument was implemented in a larger sample. The resulting numeric data were analyzed to evaluate the psychometric properties of the revised CAM instrument.
SETTING: Data were collected from patients who were receiving care from the infectious disease clinic of a large, public, urban hospital in the Southeastern United States.
SUBJECTS: Patients were eligible to participate if they (1) were receiving their care from the clinic, (2) had an AIDS diagnosis, (3) were identified as African-American, (4) were > or =21 years of age, (5) spoke English, and (6) were not cognitively impaired. MEASURES: Focus groups in phase 1 were conducted with a semistructured focus group guide. Participants also completed a basic sociodemographic survey. Phase 2 participants used programmed laptops to answer questions about their CAM use and several sociodemographic questions.
RESULTS: Information from the focus groups prompted some substantive revisions in the already-existing CAM survey. The revised instrument had satisfactory face validity and adequate test-retest reliability (r = 0.79). Furthermore, the instrument factored in a manner that was interpretable and consistent with prior findings.
CONCLUSIONS: In order for human immunodeficiency virus health care providers to provide the best care to their patients, they need to be informed about the types and frequency of CAM use among their patients. This can be accomplished by methodologically developing CAM instruments, rigorously implementing and assessing these instruments, and then disseminating the findings to researchers and practitioners.

Entities:  

Mesh:

Year:  2010        PMID: 20455786      PMCID: PMC3110866          DOI: 10.1089/acm.2009.0329

Source DB:  PubMed          Journal:  J Altern Complement Med        ISSN: 1075-5535            Impact factor:   2.579


  34 in total

1.  Drug interaction between St John's wort and nevirapine.

Authors:  M M de Maat; R M Hoetelmans; R A Math t; E C van Gorp; P L Meenhorst; J W Mulder; J H Beijnen
Journal:  AIDS       Date:  2001-02-16       Impact factor: 4.177

2.  Demographic and health-related correlates to visits to complementary and alternative medical providers.

Authors:  R B Bausell; W L Lee; B M Berman
Journal:  Med Care       Date:  2001-02       Impact factor: 2.983

3.  The effect of garlic supplements on the pharmacokinetics of saquinavir.

Authors:  Stephen C Piscitelli; Aaron H Burstein; Nada Welden; Keith D Gallicano; Judith Falloon
Journal:  Clin Infect Dis       Date:  2001-12-05       Impact factor: 9.079

4.  Use of alternative medicine in a sample of HIV-positive gay men: an exploratory study of prevalence and user characteristics.

Authors:  H M Knippels; J J Weiss
Journal:  AIDS Care       Date:  2000-08

5.  Sociodemographic determinants of the utilization of specific types of complementary and alternative medicine: an analysis based on a nationally representative survey sample.

Authors:  Lisa Conboy; Sonal Patel; Ted J Kaptchuk; Bobbie Gottlieb; David Eisenberg; Delores Acevedo-Garcia
Journal:  J Altern Complement Med       Date:  2005-12       Impact factor: 2.579

6.  Variation in complementary and alternative medicine (CAM) use across racial/ethnic groups and the development of ethnic-specific measures of CAM use.

Authors:  An-Fu Hsiao; Mitchell D Wong; Michael S Goldstein; Hong-Jian Yu; Ronald M Andersen; E Richard Brown; Lida M Becerra; Neil S Wenger
Journal:  J Altern Complement Med       Date:  2006-04       Impact factor: 2.579

7.  Physician-patient communication about complementary and alternative medical therapies: a survey of physicians caring for patients with human immunodeficiency virus infection.

Authors:  M K Wynia; D M Eisenberg; I B Wilson
Journal:  J Altern Complement Med       Date:  1999-10       Impact factor: 2.579

8.  Measurement of parenting self-efficacy and outcome expectancy related to discussions about sex.

Authors:  C DiIorio; W N Dudley; D T Wang; J Wasserman; M Eichler; L Belcher; C West-Edwards
Journal:  J Nurs Meas       Date:  2001

9.  Do cancer patients with a poor prognosis use complementary and alternative medicine more often than others?

Authors:  Agnete Egilsdatter Kristoffersen; Vinjar Fønnebø; Arne J Norheim
Journal:  J Altern Complement Med       Date:  2009-01       Impact factor: 2.579

10.  HIV prevalence estimates--United States, 2006.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2008-10-03       Impact factor: 17.586

View more
  3 in total

1.  Prevalence and predictors of complementary and alternative medicine use in African-Americans with acquired immune deficiency syndrome.

Authors:  Ashli Owen-Smith; Frances McCarty; Dana Hankerson-Dyson; Ralph Diclemente
Journal:  Focus Altern Complement Ther       Date:  2012-02-16

2.  The reasons for using acupuncture for pain relief.

Authors:  Roghyeh Sadeghi; Mohamad Ali Heidarnia; Mansoure Zagheri Tafreshi; Maryam Rassouli; Hamid Soori
Journal:  Iran Red Crescent Med J       Date:  2014-09-05       Impact factor: 0.611

Review 3.  Neurobiological Mechanism of Acupuncture for Relieving Visceral Pain of Gastrointestinal Origin.

Authors:  Fang Zhang; Luyi Wu; Jimeng Zhao; Tingting Lv; Zhihai Hu; Zhijun Weng; Shuoshuo Wang; Huangan Wu; Huirong Liu
Journal:  Gastroenterol Res Pract       Date:  2017-01-24       Impact factor: 2.260

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.